drugset / Trial / NCT05410301
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A prospective, open label, single-center, early feasibility trial will be conducted to assess the safety and feasibility of a home-based Static Magnetic and Electric (sBE) device applied for 8 hours/day during sleep in adult participants with recurrent glioblastoma (rGBM) at their first relapse.
Timeline
- Start
- 2023-04
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Lomustine | Small molecule | — | — |